Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Cancer|April 25, 2003
Hypersensitivity and idiosyncratic reactions to oxaliplatinRebecca R Thomas, Mary G Quinn, Barbara Schuler, et al.
Anticancer Research|May 13, 2015
Kaempferol Is an Anti-Inflammatory Compound with Activity towards NF-κB Pathway ProteinsOnat Kadioglu, Janine Nass, Mohamed E M Saeed, et al.
Planta Medica|November 1, 2008
Screening for anti-inflammatory activity of 12 Arnica (Asteraceae) species assessed by inhibition of NF-kappaB and release of human neutrophil elastaseCatarina Ekenäs, Anna Zebrowska, Barbara Schuler, et al.
Lung Cancer (Amsterdam, Netherlands)|September 12, 2009
Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapyRaffit Hassan, Charles Schweizer, Kun F Lu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
Impact of two weekly schedules of oral eniluracil given with fluorouracil and leucovorin on the duration of dihydropyrimidine dehydrogenase inhibitionBruce Keith, Xiao-Du Guo, Suzanne Zentko, et al.
BMC Cancer|September 20, 2005
Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancerGregory D Leonard, Maurice A Wright, Mary G Quinn, et al.
Cancer Chemotherapy and Pharmacology|April 23, 2003
Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly scheduleXiao-Du Guo, Nancy Harold, M Wasif Saif, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2005
A phase I pharmacologic and pharmacogenetic trial of sequential 24-hour infusion of irinotecan followed by leucovorin and a 48-hour infusion of fluorouracil in adult patients with solid tumorsMaurice A Wright, Geraldine Morrison, Pengxin Lin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group StudyChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Pageof 1